Chlornaphazine

Chlornaphazine is a chemotherapy drug that was used in the past for the treatment of certain blood disorders, including Hodgkin's lymphoma and other types of lymphoma. It is a derivative of naphthalene and contains chlorine, which is responsible for its antineoplastic (cancer-fighting) properties. However, due to its association with severe side effects, including an increased risk of developing secondary cancers, its use has been largely discontinued in clinical practice.
History[edit]
Chlornaphazine was developed in the mid-20th century as part of a series of chemical investigations into the therapeutic potential of naphthalene derivatives. Its efficacy in treating certain blood cancers was recognized, leading to its adoption in some treatment protocols. However, as the understanding of its toxicological profile increased, particularly its carcinogenic potential, its use was phased out in favor of safer and more effective treatments.
Mechanism of Action[edit]
The mechanism of action of chlornaphazine involves the alkylation of DNA, which leads to the cross-linking of DNA strands, thereby inhibiting DNA synthesis and function. This results in the death of rapidly dividing cells, a characteristic of cancer cells. However, this mechanism is not selective for cancer cells, leading to the damage of healthy cells as well, which contributes to the drug's toxicity.
Side Effects[edit]
The side effects of chlornaphazine are significant and include both acute and long-term risks. Acute side effects are similar to those of other chemotherapy agents and include nausea, vomiting, alopecia (hair loss), and myelosuppression (decreased production of blood cells), leading to an increased risk of infection and bleeding. The most concerning long-term side effect is the increased risk of secondary cancers, particularly acute leukemia, which has been observed in patients treated with chlornaphazine.
Current Status[edit]
Due to its severe side effects and the development of more effective and safer treatments, chlornaphazine is no longer used in clinical practice. Its history, however, provides important lessons in the development of chemotherapy drugs, highlighting the need for a careful balance between efficacy and safety.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian